Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

Cancer

Volumn 103, Issue 1, 2005, Pages 52-58

  Yang, Gong ^a,b   Shu, Xiao Ou ^a,b   Ruan, Zhi Xian ^c   Cai, Qiu Yin ^a,b   Jin, Fan ^c   Gao, Yu Tang ^c   Zheng, Wei ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

Author keywords

Breast carcinoma; GSTM1; GSTP1; GSTT1; Polymorphism; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GENOMIC DNA; GLUTATHIONE TRANSFERASE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; ALLELE; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENOTYPE; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 10844234923     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20729     Document Type: Article

References (36)

1. Russin MR, Goldstein LJ. Chemotherapy in breast cancer. In: Torosian MH, editor. Breast cancer. Totowa, NJ: Humana Press, 2002:145-159.
2. Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer. 2003;97(8 Suppl):2076-2082.
3. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003;54:437-452.
4. Coles BF, Kadlubar FF. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors. 2003;17:115-130.
5. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J. 2004; 4:143-153.
6. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600.
7. London SJ, Yuan JM, Chung FL, et al. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet. 2000;356:724-729.
8. Hamajima N, Takezaki T, Tajima K. Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev. 2002;3:197-206.
9. Park SK, Yoo KY, Lee SJ, et al. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics. 2000;10:301-309.
10. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys. 1999; 366:89-94.
11. Pandya U, Srivastava SK, Singhal SS, et al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun. 2000;278: 258-262.
12. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P. Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res. 1999;1:81-87.
13. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001;61: 7130-7135.
14. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase Pl Ile105Val polymorphism. Cancer Res. 2000;60:5621-5624.
15. Goode EL, Dunning AM, Kuschel B, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002;62:3052-3057.
16. Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer. 2003;103:810-814.
17. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer. 2000;87:295-300.
18. Shu XO, Gao YT, Cai Q, et al. Genetic polymorphisms in the TGF-β1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64:836-839.
19. Egan KM, Cai Q, Shu XO, et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2004;13:197-204.
20. Salinas AE, Wong MG. Glutathione S-transferases-a review. Curr Med Chem. 1999;6:279-309.
21. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 2003;16:558-565.
22. Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998;4:1469-1474.
23. Harpole DH Jr., Moore MB, Herndon JE II, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7:562-569.
24. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 1999;25:387-394.
25. Kigawa J, Minagawa Y, Kanamori Y, et al. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer. 1998;82:697-702.
26. Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase TT, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999;5:4097-4104.
27. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002;94:936-942.
28. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res. 1998;58:65-70.
29. Lallas TA, McClain SK, Shahin MS, Buller RE. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:587-590.
30. Yang P, Yokomizo A, Tazelaar HD, et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer. 2002;35:221-229.
31. Sala A, Lanciotti M, Valsecchi MG, et al. Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. Leukemia. 2003;17:981-983.
32. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002;100: 67-71.
33. Howells RE, Redman CW, Dhar KK, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998;4:2439-2445.
34. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2003;12:527-533.
35. Voso MT, D'Alo' F, Putzulu R, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood. 2002;100: 2703-2707.
36. Davies SM, Robison LL, Buckley JD, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol. 2001;19: 1279-1287.